Benitec Biopharma (BNTC) vs Cabaletta Bio (CABA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cabaletta Bio (CABA) has outperformed Benitec Biopharma (BNTC) over the past year, losing 15.1% versus a loss of 34.8%. Over five years, CABA leads with a -83.9% price change compared with -85.3% for BNTC. Cabaletta Bio is the larger company by market cap ($334.0 million vs $313.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | CABA |
|---|---|---|
| Share price | $8.99 | $1.97 |
| Market cap | $313.60M | $334.00M |
| 1-day change | -0.11% | -2.48% |
| YTD return | -33.26% | -10.05% |
| 1-year return | -34.76% | -15.09% |
| 5-year return | -85.27% | -83.93% |
| EPS (TTM) | $-0.98 | $-1.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.76 | $4.23 |
| 52-week low | $8.52 | $1.83 |
| Distance from 52-week high | -46.36% | -53.43% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +170.63% | +572.59% |
| Average volume | 150.34K | 4.71M |
| Shares outstanding | 34.88M | 169.55M |
| Employees | 24 | 154 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CABA has outperformed BNTC by 19.7 percentage points over the past year.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Healthcare · Biotechnology · 24 employees
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Healthcare · Biotechnology · 154 employees
BNTC vs CABA FAQ
Which is bigger, Benitec Biopharma or Cabaletta Bio?
Cabaletta Bio (CABA) is larger, with a market capitalization of $334.00M compared with $313.60M for Benitec Biopharma (BNTC).
Which stock has performed better over the past year, BNTC or CABA?
CABA returned -15.09% over the past 12 months, compared with -34.76% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Cabaletta Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.